The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The role of real-world evidence in the evaluation of new drugs
Natacha Bolaños, Lymphoma Coalition Europe, Madrid, Spain, discusses the role of real-world evidence in research and drug approvals. She notes that while real-world data is often retrospective and not originally collected for research or regulatory purposes, it can address recruitment challenges in clinical trials. Ms Bolaños advocates for clinical trials with inclusion criteria that better reflect real-world patient populations and emphasizes the importance of integrating quality of life (QoL) data into research. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
